mRNA-4157
- Generic Name
- mRNA-4157
A Clinical Study of V940 and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
- Conditions
- Malignant Melanoma
- Interventions
- First Posted Date
- 2025-05-07
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 160
- Registration Number
- NCT06961006
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
- Conditions
- Urinary Bladder NeoplasmsNon-Muscle Invasive Bladder NeoplasmsCarcinoma in Situ
- Interventions
- First Posted Date
- 2025-02-18
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 308
- Registration Number
- NCT06833073
- Locations
- 🇺🇸
University of Missouri Health Care ( Site 0126), Columbia, Missouri, United States
🇺🇸NHO Revive Research Institute, LLC ( Site 0137), Lincoln, Nebraska, United States
🇺🇸OHSU Knight Cancer Institute - South Waterfront ( Site 0110), Portland, Oregon, United States
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2024-10-02
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 680
- Registration Number
- NCT06623422
- Locations
- 🇺🇸
Providence St. Jude Medical Center ( Site 0106), Fullerton, California, United States
🇺🇸Ellis Fischel Cancer Center ( Site 0133), Columbia, Missouri, United States
🇺🇸Lake Regional Hospital-Cancer Center ( Site 0123), Osage Beach, Missouri, United States
A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).
- Conditions
- Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 272
- Registration Number
- NCT06307431
- Locations
- 🇦🇺
Westmead Hospital ( Site 1501), Westmead, New South Wales, Australia
🇺🇸City of Hope Comprehensive Cancer Center-Medical Oncology ( Site 0104), Duarte, California, United States
🇺🇸UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro, Los Angeles, California, United States
A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
- Conditions
- Bladder Cancer
- Interventions
- Other: PlaceboBiological: Enfortumab VedotinProcedure: Surgery (RC plus PLND)
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 230
- Registration Number
- NCT06305767
- Locations
- 🇺🇸
UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro ( Site 0104), Los Angeles, California, United States
🇺🇸AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlandoc ( Site 0102), Orlando, Florida, United States
🇺🇸Icahn School of Medicine at Mount Sinai ( Site 0101), New York, New York, United States
A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007).
- Conditions
- Carcinoma, Squamous CellSkin Neoplasms
- Interventions
- First Posted Date
- 2024-03-06
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1012
- Registration Number
- NCT06295809
- Locations
- 🇮🇱
Sheba Medical Center ( Site 2200), Ramat Gan, Israel
🇳🇴Oslo universitetssykehus, Radiumhospitalet ( Site 2400), Oslo, Norway
🇷🇴Sigmedical Services SRL ( Site 2603), Suceava, Romania
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-10-11
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 868
- Registration Number
- NCT06077760
- Locations
- 🇺🇸
Alaska Oncology and Hematology ( Site 0039), Anchorage, Alaska, United States
🇺🇸YUMA REGIONAL MEDICAL CENTER CANCER CENTER ( Site 0020), Yuma, Arizona, United States
🇺🇸UCLA Clinical & Translational Research Center (CTRC) ( Site 0059), Los Angeles, California, United States
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
- Conditions
- Melanoma
- Interventions
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1089
- Registration Number
- NCT05933577
- Locations
- 🇨🇳
Chang Gung Memorial Hospital at Kaohsiung (Site 4000), Kaohsiung, Taiwan
🇨🇳National Cheng Kung University Hospital-Clinical Trial Center ( Site 4004), Tainan, Taiwan
🇨🇳National Taiwan University Hospital (Site 4001), Taipei, Taiwan
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)
- First Posted Date
- 2019-04-01
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 267
- Registration Number
- NCT03897881
- Locations
- 🇺🇸
University of Arizona, Tucson, Arizona, United States
🇺🇸California Pacific Medical Center Research Institute -CPMCRI, San Francisco, California, United States
🇺🇸Angeles Clinic and Research Institute, Santa Monica, California, United States
Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2017-10-18
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 242
- Registration Number
- NCT03313778
- Locations
- 🇺🇸
Providence Portland Medical Center, Portland, Oregon, United States
🇺🇸UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸SCRI, Oncology Partners, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.